Publications

. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025-06-21; doi: 10.1016/S0140-6736(25)01040-2. PubMed PMID: 40473448.

. Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring. Nat Rev Clin Oncol. 2025-06-09; doi: 10.1038/s41571-025-01040-y. PubMed PMID: 40490477.

. Aged and BRCA mutated stromal cells drive epithelial cell transformation. Cancer Discov. 2025-06-03; doi: 10.1158/2159-8290.CD-24-0805. PubMed PMID: 40084985; PMCID: PMC12130807.

. Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial. JAMA Surg. 2025-05-07; doi: 10.1001/jamasurg.2025.1072. PubMed PMID: 40332918; PMCID: PMC12060017.

. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. J Clin Oncol. 2024-10-20;JCO2301995. doi: 10.1200/JCO.23.01995. PubMed PMID: 39047219; PMCID: PMC11469649.

. Electronic Health Record-Based Nudge Intervention and Axillary Surgery in Older Women With Breast Cancer: A Nonrandomized Controlled Trial. JAMA Surg. 2024-10-01; doi: 10.1001/jamasurg.2024.2407. PubMed PMID: 39018053; PMCID: PMC11255976.

. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024-06-10;42(17):2061-2070. doi: 10.1200/JCO.23.01544. PubMed PMID: 38531002; PMCID: PMC11514296.

. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Clin Cancer Res. 2024-05-01; doi: 10.1158/1078-0432.CCR-23-1977. PubMed PMID: 38376912; PMCID: PMC11061597.

. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024-04-20;JCO2301428. doi: 10.1200/JCO.23.01428. PubMed PMID: 38335467; PMCID: PMC11095853.

. Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. Cancer Lett. 2024-04-01;216679. doi: 10.1016/j.canlet.2024.216679. PubMed PMID: 38307411; PMCID: PMC10939791.

. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou J Clin Oncol. 2024-03-20;JCO2301994. doi: 10.1200/JCO.23.01994. PubMed PMID: 38194616; PMCID: PMC10950161.

. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients. Am J Hematol. 2024-03-01; doi: 10.1002/ajh.27212. PubMed PMID: 38258329; PMCID: PMC11552450.

. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024-01-12;OF1-OF14. doi: 10.1158/2159-8290.CD-23-0964. PubMed PMID: 37861461; PMCID: PMC10784743.

. Project Confirm: Accelerated Drug Approvals for CML-Letter. Clin Cancer Res. 2024-01-05;30(1):235-236. doi: 10.1158/1078-0432.CCR-23-2630. PubMed PMID: 38178775; PMCID: PMC10783536.

. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2. EClinicalMedicine. 2023-12-01;66102317. doi: 10.1016/j.eclinm.2023.102317. PubMed PMID: 38192592; PMCID: PMC10772260.

. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023-07-10;41(20):3565-3575. doi: 10.1200/JCO.22.02570. PubMed PMID: 37406456.

. Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit. Clin Cancer Res. 2023-02-16;29(4):723-730. doi: 10.1158/1078-0432.CCR-22-1768. PubMed PMID: 36595540; PMCID: PMC11232033.

. Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation. Cancer Res. 2022-12-16;82(24):4680-4693. doi: 10.1158/0008-5472.CAN-22-1294. PubMed PMID: 36219681; PMCID: PMC9755968.

. All Optimal Dosing Roads Lead to Therapeutic Drug Monitoring-Why Take the Slow Lane. JAMA Oncol. 2022-12-01;8(12):1733-1735. doi: 10.1001/jamaoncol.2022.4452. PubMed PMID: 36264552; PMCID: PMC9772116.

. Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful? Nat Rev Clin Oncol. 2022-12-01;19(12):745-746. doi: 10.1038/s41571-022-00684-4. PubMed PMID: 36042383; PMCID: PMC9675711.

. HLA-A*03 and response to immune checkpoint blockade in patients with cancer. Lancet Oncol. 2022-03-01;23(3):e99. doi: 10.1016/S1470-2045(22)00086-9. PubMed PMID: 35240100.

. Recurrent Human Papillomavirus-Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation. Clin Cancer Res. 2021-11-15;27(22):6250-6264. doi: 10.1158/1078-0432.CCR-20-4789. PubMed PMID: 34407971; PMCID: PMC8611487.

. Ovarian function suppression as a potential mechanism of chemotherapy. EBioMedicine. 2021-08-01;70103489. doi: 10.1016/j.ebiom.2021.103489. PubMed PMID: 34280778; PMCID: PMC8318981.

. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021-07-20;39(21):2367-2374. doi: 10.1200/JCO.20.02824. PubMed PMID: 33739848; PMCID: PMC8462554.

. DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells. Leukemia. 2021-07-01;35(7):1925-1932. doi: 10.1038/s41375-020-01047-7. PubMed PMID: 33139859; PMCID: PMC10165724.

. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021-06-01;16(6):1017-1029. doi: 10.1016/j.jtho.2021.02.010. PubMed PMID: 33676017.

. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. ACS Nano. 2021-05-25;15(5):8069-8086. doi: 10.1021/acsnano.1c00629. PubMed PMID: 33826850.

. Reply to K. Hashimoto and A. Shimomura. J Clin Oncol. 2021-05-01;39(13):1507-1508. doi: 10.1200/JCO.20.03477. PubMed PMID: 33630658.

. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021-04-01;4(4):e216322. doi: 10.1001/jamanetworkopen.2021.6322. PubMed PMID: 33856473; PMCID: PMC8050744.

. Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma. Leukemia. 2021-04-01;35(4):1193-1196. doi: 10.1038/s41375-020-01017-z. PubMed PMID: 32814841.

. Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. J Clin Oncol. 2021-01-20;39(3):254-255. doi: 10.1200/JCO.20.02963. PubMed PMID: 33332192.

. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. J Immunother Cancer. 2020-10-01;8(2): doi: 10.1136/jitc-2020-000810. PubMed PMID: 33077513; PMCID: PMC7574947.

. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clin Cancer Res. 2020-08-15;26(16):4233-4241. doi: 10.1158/1078-0432.CCR-20-0152. PubMed PMID: 32371537; PMCID: PMC7724952.

. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020-06-01;80(9):883-892. doi: 10.1007/s40265-020-01320-0. PubMed PMID: 32436070; PMCID: PMC8579493.

. Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol. 2020-03-01;21(3):318-319. doi: 10.1016/S1470-2045(19)30857-5. PubMed PMID: 32035019.

. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020-02-10;38(5):444-453. doi: 10.1200/JCO.19.01455. PubMed PMID: 31821109; PMCID: PMC7007289.

. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019-12-14;394(10215):2155-2164. doi: 10.1016/S0140-6736(19)32514-0. PubMed PMID: 31813636; PMCID: PMC7199428.

. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. Clin Cancer Res. 2019-10-01;25(19):5752-5758. doi: 10.1158/1078-0432.CCR-18-3453. PubMed PMID: 31308059; PMCID: PMC6820348.

. CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019-10-01;20(10):1329-1330. doi: 10.1016/S1470-2045(19)30507-8. PubMed PMID: 31494036.

. Artificial intelligence-directed prognostication of breast cancer. EBioMedicine. 2019-08-01;466-7. doi: 10.1016/j.ebiom.2019.07.073. PubMed PMID: 31378696; PMCID: PMC6712046.

. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019-06-01;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. PubMed PMID: 30836094.

. Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res. 2019-03-01;25(5):1441-1442. doi: 10.1158/1078-0432.CCR-18-3078. PubMed PMID: 30413524; PMCID: PMC6415532.

. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019-01-01;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. PubMed PMID: 30509771; PMCID: PMC6691732.

. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018-12-04;6(1):137. doi: 10.1186/s40425-018-0460-5. PubMed PMID: 30514386; PMCID: PMC6278156.

. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res. 2018-09-15;78(18):5398-5407. doi: 10.1158/0008-5472.CAN-18-0316. PubMed PMID: 30042150; PMCID: PMC6139073.

. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. J Thorac Oncol. 2018-08-01;13(8):e135-e136. doi: 10.1016/j.jtho.2018.02.031. PubMed PMID: 30049372.

. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018-05-14;6(1):35. doi: 10.1186/s40425-018-0342-x. PubMed PMID: 29754585; PMCID: PMC5950135.

. The Future of Radiology. JAMA. 2017-12-05;318(21):2141. doi: 10.1001/jama.2017.16659. PubMed PMID: 29209714.

. TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clin Cancer Res. 2017-12-01;23(23):7324-7332. doi: 10.1158/1078-0432.CCR-17-1561. PubMed PMID: 28899969; PMCID: PMC5898434.

. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017-09-01;5922-32. doi: 10.1016/j.ctrv.2017.06.004. PubMed PMID: 28719836.

. TACT2: improving treatment tolerability in early breast cancer. Lancet Oncol. 2017-07-01;18(7):843-845. doi: 10.1016/S1470-2045(17)30437-0. PubMed PMID: 28677561.

. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2017-05-01;15(5):555-562. doi: 10.6004/jnccn.2017.0058. PubMed PMID: 28476735.

. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017-04-24;10(1):94. doi: 10.1186/s13045-017-0453-8. PubMed PMID: 28434396; PMCID: PMC5402171.

. Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. Lancet Oncol. 2017-04-01;18(4):428-429. doi: 10.1016/S1470-2045(17)30150-X. PubMed PMID: 28238596.

. nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings. Exp Hematol Oncol. 2017-03-22;67. doi: 10.1186/s40164-017-0066-5. PubMed PMID: 28344858; PMCID: PMC5361712.

. Interfacial Ca(2+) environments in nanocrystalline apatites revealed by dynamic nuclear polarization enhanced (43)Ca NMR spectroscopy. Nat Commun. 2017-01-27;814104. doi: 10.1038/ncomms14104. PubMed PMID: 28128197; PMCID: PMC5290151.

. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016-12-20;490. doi: 10.1186/s40425-016-0188-z. PubMed PMID: 28018601; PMCID: PMC5168808.

. Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions. J Clin Oncol. 2016-11-10;34(32):3941-3942. doi: 10.1200/JCO.2016.67.2949. PubMed PMID: 27551134.

. Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation? Clin Cancer Res. 2016-10-15;22(20):4963-4965. doi: 10.1158/1078-0432.CCR-16-1513. PubMed PMID: 27521446; PMCID: PMC5154749.

. Is there room for bevacizumab in metastatic breast cancer? Lancet Oncol. 2016-09-01;17(9):1175-6. doi: 10.1016/S1470-2045(16)30295-9. PubMed PMID: 27501769.

. Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. J Clin Oncol. 2016-07-10;34(20):2430-1. doi: 10.1200/JCO.2016.67.2790. PubMed PMID: 27185845.

. Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol. 2016-01-10;34(2):110-6. doi: 10.1200/JCO.2014.59.7302. PubMed PMID: 26392101; PMCID: PMC4980565.

. Bisphosphonates, bone, and breast cancer recurrence. Lancet. 2015-10-03;386(10001):1319-1320. doi: 10.1016/S0140-6736(15)61163-1. PubMed PMID: 26211825.

. Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet? JAMA Oncol. 2015-09-01;1(6):732-3. doi: 10.1001/jamaoncol.2015.1926. PubMed PMID: 26181495; PMCID: PMC4696392.

. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res. 2015-05-01;21(9):2020-8. doi: 10.1158/1078-0432.CCR-14-0586. PubMed PMID: 25348512; PMCID: PMC4411210.

. A phase i study of DMS612, a novel bifunctional alkylating agent. Clin Cancer Res. 2015-02-15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. PubMed PMID: 25467180; PMCID: PMC4755291.

. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015-01-15;21(2):286-94. doi: 10.1158/1078-0432.CCR-14-1790. PubMed PMID: 25424847; PMCID: PMC4297523.

. Length of chemotherapy and use of bevacizumab for breast cancer. Lancet Oncol. 2014-11-01;15(12):1285-7. doi: 10.1016/S1470-2045(14)70480-2. PubMed PMID: 25439683.

. Stereotactic body radiation therapy is a cost-effective alternative to intensity-modulated radiation therapy. J Clin Oncol. 2014-10-20;32(30):3451. doi: 10.1200/JCO.2014.56.6737. PubMed PMID: 25185091.

. Breast cancer: Zoledronic acid--more than just a bone drug. Nat Rev Clin Oncol. 2014-10-01;11(10):564-5. doi: 10.1038/nrclinonc.2014.152. PubMed PMID: 25200411.

. To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN. Clin Cancer Res. 2014-09-01;20(17):4673-88. doi: 10.1158/1078-0432.CCR-14-0363. PubMed PMID: 24919570; PMCID: PMC4160843.